Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 224

1.

Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modelling approaches to estimate and extrapolate survival outcomes.

Goeree R, Villeneuve J, Goeree J, Penrod JR, Orsini L, Tahami Monfared AA.

J Med Econ. 2016 Feb 5:1-33. [Epub ahead of print]

PMID:
26850122
2.

Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial.

Fedorko L, Bowen JM, Jones W, Oreopoulos G, Goeree R, Hopkins RB, O'Reilly DJ.

Diabetes Care. 2016 Jan 6. pii: dc152001. [Epub ahead of print]

PMID:
26740639
3.

Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension.

Akioyamen L, Levine M, Sherifali D, O'Reilly D, Frankfurter C, Pullenayegum E, Goeree R, Tsoi B.

J Am Soc Hypertens. 2016 Jan;10(1):55-69.e1. doi: 10.1016/j.jash.2015.11.005. Epub 2015 Dec 1.

PMID:
26684588
4.

Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting.

Kamboj L, Oh P, Levine M, Kammila S, Casey W, Harterre D, Goeree R.

Int J Cardiol. 2016 Jan 15;203:893-9. doi: 10.1016/j.ijcard.2015.11.037. Epub 2015 Nov 10.

PMID:
26613572
6.

Zrx Mcdm: A Fully Flexible Tool to Support The Local Adaptation of Multiple-Criteria Decision Criteria In Health Care.

Zah V, Thompson S, Berjan M, Goeree R.

Value Health. 2015 Nov;18(7):A703. doi: 10.1016/j.jval.2015.09.2634. Epub 2015 Oct 20. No abstract available.

PMID:
26533938
7.

Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.

Moshyk A, Martel MJ, Tahami Monfared AA, Goeree R.

J Med Econ. 2016 Feb;19(2):181-92. doi: 10.3111/13696998.2015.1106546. Epub 2015 Nov 11.

PMID:
26453248
8.

Pulmonary Rehabilitation in Ontario: A Cross-Sectional Survey.

Bowen JM, Campbell K, Sutherland S, Bartlett A, Brooks D, Qureshi R, Goldstein R, Gershon AS, Prevost S, Samis L, Kaplan AG, Hopkins RB, MacDougald C, Nunes E, O'Reilly DJ, Goeree R.

Ont Health Technol Assess Ser. 2015 Mar 1;15(8):1-67. eCollection 2015.

9.

Colon Capsule Endoscopy for the Detection of Colorectal Polyps: An Economic Analysis.

Palimaka S, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2015 Jul 1;15(15):1-43. eCollection 2015.

10.

Capsule Endoscopy in the Assessment of Obscure Gastrointestinal Bleeding: An Economic Analysis.

Palimaka S, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2015 Feb 1;15(2):1-32. eCollection 2015.

11.

Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments.

Boutis K, von Keyserlingk C, Willan A, Narayanan UG, Brison R, Grootendorst P, Plint AC, Parker M, Goeree R.

Ann Emerg Med. 2015 Nov;66(5):455-463.e4. doi: 10.1016/j.annemergmed.2015.05.027. Epub 2015 Jul 14.

PMID:
26187612
12.

Barriers and facilitators influencing ethical evaluation in health technology assessment.

Assasi N, Schwartz L, Tarride JE, O'Reilly D, Goeree R.

Int J Technol Assess Health Care. 2015 Jan;31(3):113-23. doi: 10.1017/S026646231500032X.

PMID:
26179275
13.

Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations.

Tsoi B, O'Reilly D, Jegathisawaran J, Tarride JE, Blackhouse G, Goeree R.

BMC Res Notes. 2015 Jun 17;8:244. doi: 10.1186/s13104-015-1202-0.

14.

Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management.

Tsoi B, Blackhouse G, Ferrazzi S, Reade CJ, Chen I, Goeree R.

Clinicoecon Outcomes Res. 2015 Apr 17;7:213-25. doi: 10.2147/CEOR.S78115. eCollection 2015.

15.

Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies.

Tsoi B, Goeree R, Jegathisawaran J, Tarride JE, Blackhouse G, O'Reilly D.

Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):451-63. doi: 10.1586/14737167.2015.1021336. Epub 2015 Mar 2. Review.

PMID:
25728942
16.

Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.

Tsoi B, O'Reilly D, Masucci L, Drummond M, Goeree R.

J Popul Ther Clin Pharmacol. 2015;22(1):e78-89. Epub 2015 Feb 21.

17.

Evidence-based decision-making 3: Health technology assessment.

O'Reilly D, Campbell K, Vanstone M, Bowen JM, Schwartz L, Assasi N, Goeree R.

Methods Mol Biol. 2015;1281:417-41. doi: 10.1007/978-1-4939-2428-8_25.

PMID:
25694325
18.

A literature review of economic evaluations for a neglected tropical disease: human African trypanosomiasis ("sleeping sickness").

Sutherland CS, Yukich J, Goeree R, Tediosi F.

PLoS Negl Trop Dis. 2015 Feb 5;9(2):e0003397. doi: 10.1371/journal.pntd.0003397. eCollection 2015 Feb. Review.

19.

Economic burden of illness associated with diabetic foot ulcers in Canada.

Hopkins RB, Burke N, Harlock J, Jegathisawaran J, Goeree R.

BMC Health Serv Res. 2015 Jan 22;15:13. doi: 10.1186/s12913-015-0687-5.

20.

Processes, contexts, and rationale for disinvestment: a protocol for a critical interpretive synthesis.

Wilson MG, Ellen ME, Lavis JN, Grimshaw JM, Moat KA, Shemer J, Sullivan T, Garner S, Goeree R, Grilli R, Peffer J, Samra K.

Syst Rev. 2014 Dec 11;3:143. doi: 10.1186/2046-4053-3-143. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk